Browse Human Gene Sets

Gene set name:

 
  (Enter full or partial name)

By first letter:

 

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

By collection:

[about the MSigDB Human collections]

  • H (hallmark gene sets, 50 gene sets)
  • C1 (positional gene sets, 302 gene sets)
  • C2 (curated gene sets, 7837 gene sets)
    • CGP (chemical and genetic pertubations, 3560 gene sets)
    • CP (canonical pathways, 4277 gene sets)
  • C3 (regulatory gene sets, 3712 gene sets)
    • MIR (microRNA targets, 2598 gene sets)
    • TFT (all transcription factor targets, 1114 gene sets)
      • TFT:GTRD (GTRD transcription factor targets, 504 gene sets)
      • TFT:TFT_LEGACY (legacy transcription factor targets, 610 gene sets)
  • C4 (computational gene sets, 1006 gene sets)
    • 3CA (Curated Cancer Cell Atlas gene sets, 148 gene sets)
    • CGN (cancer gene neighborhoods, 427 gene sets)
    • CM (cancer modules, 431 gene sets)
  • C5 (ontology gene sets, 15849 gene sets)
    • GO (Gene Ontology, 9917 gene sets)
      • GO:BP (GO biological process, 6905 gene sets)
      • GO:CC (GO cellular component, 1094 gene sets)
      • GO:MF (GO molecular function, 1918 gene sets)
    • HPO (Human Phenotype Ontology, 5932 gene sets)
  • C6 (oncogenic gene sets, 189 gene sets)
  • C7 (immunologic gene sets, 5219 gene sets)
    • IMMUNESIGDB (ImmuneSigDB gene sets, 4872 gene sets)
    • VAX (vaccine response gene sets, 347 gene sets)
  • C8 (cell type signature gene sets, 866 gene sets)
  • C9 (computational perturbation signature gene sets, 62 gene sets)

Click on a gene set name to view its gene set page.

ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_1DY_DN
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_1DY_UP
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_3DY_DN
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_3DY_UP
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_6HR_DN
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_6HR_UP
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_7DY_DN
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_7DY_UP
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_HIGH_IGM_RESPONDERS_3DY_7D_DN
ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_LOW_IGM_RESPONDERS_6HY_1DY_UP
BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_HIGH_RESPONDERS_1DY_3DY_POSITIVE_PREDICTIVE_OF_TITER
BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_HIGH_RESPONDERS_1DY_TOP_FUNCTIONAL_NETWORK_POSITIVE
BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_LOW_RESPONDERS_1DY_POSITIVE_PREDICTIVE_OF_TITER
CAO_BLOOD_FLUMIST_AGE_05_14YO_1DY_DN
CAO_BLOOD_FLUMIST_AGE_05_14YO_1DY_UP
CAO_BLOOD_FLUMIST_AGE_05_14YO_30DY_DN
CAO_BLOOD_FLUMIST_AGE_05_14YO_30DY_UP
CAO_BLOOD_FLUMIST_AGE_05_14YO_7DY_DN
CAO_BLOOD_FLUMIST_AGE_05_14YO_7DY_UP
CAO_BLOOD_FLUMIST_AGE_05_14YO_CORRELATED_WITH_H3N2_VN_TITER_7DY_POSITIVE
CAO_BLOOD_FLUZONE_AGE_05_14YO_1DY_DN
CAO_BLOOD_FLUZONE_AGE_05_14YO_1DY_UP
CAO_BLOOD_FLUZONE_AGE_05_14YO_30DY_DN
CAO_BLOOD_FLUZONE_AGE_05_14YO_30DY_UP
CAO_BLOOD_FLUZONE_AGE_05_14YO_7DY_DN
CAO_BLOOD_FLUZONE_AGE_05_14YO_7DY_UP
CAO_BLOOD_FLUZONE_AGE_05_14YO_CORRELATED_WITH_H3N1_HI_TITER_1DY_POSITIVE
COLE_BLOOD_FLUMIST_QUADRIVALENT_AGE_03_17YO_7DY_UP
COLE_BLOOD_FLUZONE_FLUARIX_AGE_03_17YO_7DY_DN
DHIMAN_PBMC_ATTENUVAX_AGE_15_25YO_SUBQ_7_OR_14DY_DN
DHIMAN_PBMC_ATTENUVAX_AGE_15_25YO_SUBQ_7_OR_14DY_UP
ERWIN_COHEN_BLOOD_LIVE_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_14DY_UP
ERWIN_COHEN_BLOOD_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_UP
ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_14DY_DN
ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_DN
ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_DN
ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_UP
ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NAIVE_NOT_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP
ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NON_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_DN
ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NON_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP
ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP
FISCHER_BLOOD_PLASMA_RVSV_EBOV_AGE_18_55YO_HIGH_DOSE_3DY_DN
FLETCHER_PBMC_BCG_10W_INFANT_BCG_STIMULATED_VS_UNSTIMULATED_10W_DN
FLETCHER_PBMC_BCG_10W_INFANT_BCG_STIMULATED_VS_UNSTIMULATED_10W_UP
FLETCHER_PBMC_BCG_10W_INFANT_PPD_STIMULATED_VS_UNSTIMULATED_10W_DN
FLETCHER_PBMC_BCG_10W_INFANT_PPD_STIMULATED_VS_UNSTIMULATED_10W_UP
FOURATI_BLOOD_TWINRIX_AGE_25_83YO_RESPONDERS_VS_POOR_RESPONDERS_0DY_DN
FOURATI_BLOOD_TWINRIX_AGE_25_83YO_RESPONDERS_VS_POOR_RESPONDERS_0DY_UP
FOURATI_BLOOD_TWINRIX_AGE_65_81Y0_RESPONDERS_VS_POOR_RESPONDERS_TRAINING_SET_0DY_NETWORK_INFERENCE_UP
FOURATI_BLOOD_TWINRIX_AGE_65_81YO_RESPONDERS_VS_POOR_RESPONDERS_TRAINING_SET_0DY_NETWORK_INFERENCE_DN
FOURATI_BLOOD_TWINRIX_AGE_65_83YO_POOR_RESPONDERS_VS_RESPONDERS_0DY_NETWORK_INFERENCE_UP
FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_0DY_NEGATIVE
FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_0DY_POSITIVE
FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_14DY_NEGATIVE
FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_14DY_POSITIVE
FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_1DY_NEGATIVE
FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_1DY_POSITIVE
FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_3DY_POSITIVE
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_DN
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_336HR_SUSTAINED_UP
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_48HR_EARLY_DN
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_48HR_EARLY_UP
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_UP
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_192HR_DN
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_192HR_UP
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_336HR_DN
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_336HR_UP
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_48HR_DN
FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_48HR_UP
GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_12MO_CORRELATED_WITH_ANTIBODY_RESPONSE_NEGATIVE
GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_12MO_CORRELATED_WITH_ANTIBODY_RESPONSE_POSITIVE
GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_2MO_DN
GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_2MO_UP
GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_7MO_CORRELATED_WITH_ANTIBODY_RESPONSE_NEGATIVE
GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_7MO_CORRELATED_WITH_ANTIBODY_RESPONSE_POSITIVE
GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_STIMULATED_VS_UNSTIMULATED_0DY_VACCINATION_INDEPENDENT_DN
GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_STIMULATED_VS_UNSTIMULATED_0DY_VACCINATION_INDEPENDENT_UP
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_10DY_DN
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_10DY_UP
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_14DY_DN
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_14DY_UP
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_28DY_DN
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_28DY_UP
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_3DY_DN
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_3DY_UP
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_60DY_DN
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_60DY_UP
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_7DY_DN
GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_7DY_UP
GIAROLA_SILVA_BLOOD_INFLUENZA_A_AGE_21_51YO_3DY_UP
GIAROLA_SILVA_BLOOD_PANDEMRIX_AGE_21_51YO_30DY_UP
GIAROLA_SILVA_BLOOD_PANDEMRIX_AGE_21_51YO_3DY_UP
HARALAMBIEVA_PBMC_DRYVAX_AGE_18_40YO_STIMULATED_VS_UNSTIMULATED_9_TO_34MO_UP
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_0DY_NEGATIVE
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_0DY_POSITIVE
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LATE_GENE_EXPR_INDIVID_GENE_MODELS_PRED_PEAK_B_CELL_ELISPOT_RESP_NEGATIVE
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LATE_GENE_EXPR_INDIVID_GENE_MODELS_PRED_PEAK_B_CELL_ELISPOT_RESP_POSITIVE
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LEUK_MIGR_MAPK_ACT_CYTOK_SIG_DIAB_OF_THE_YNG_NEGATIVE
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LEUK_MIGR_MAPK_ACT_CYTOK_SIG_DIAB_OF_THE_YNG_POSITIVE
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_POSITIVE
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_3DY_NEGATIVE
HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_3DY_POSITIVE
HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_DN
HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_UP
HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_HIGH_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN
HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN
HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_UP
HARALAMBIEVA_PBMC_M_M_R_II_AGE_13_16YO_STIMULATED_VS_UNSTIMULATED_3_TO_7YR_POST_TOP_DEG_UP
HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_28DY_NEGATIVE
HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_3DY_NEGATIVE
HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_3DY_POSITIVE
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_DOWN
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP
HOEK_B_CELL_2011_2012_TIV_ADULT_1DY_UP
HOEK_B_CELL_2011_2012_TIV_ADULT_3DY_DN
HOEK_B_CELL_2011_2012_TIV_ADULT_3DY_UP
HOEK_B_CELL_2011_2012_TIV_ADULT_7DY_DN
HOEK_B_CELL_2011_2012_TIV_ADULT_7DY_UP
HOEK_MONOCYTE_2011_2012_TIV_ADULT_1DY_DN
HOEK_MONOCYTE_2011_2012_TIV_ADULT_1DY_UP
HOEK_MONOCYTE_2011_2012_TIV_ADULT_3DY_DN
HOEK_MONOCYTE_2011_2012_TIV_ADULT_3DY_UP
HOEK_MONOCYTE_2011_2012_TIV_ADULT_7DY_DN
HOEK_MONOCYTE_2011_2012_TIV_ADULT_7DY_UP
HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_1DY_DN
HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_1DY_UP
HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_3DY_DN
HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_3DY_UP
HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_7DY_DN
HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_7DY_UP
HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_1DY_DN
HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_1DY_UP
HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_3DY_DN
HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_3DY_UP
HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_7DY_DN
HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_7DY_UP
HOEK_NK_CELL_2011_2012_TIV_1D_VS_0DY_ADULT_1D_DN
HOEK_NK_CELL_2011_2012_TIV_3D_VS_0DY_ADULT_3D_DN
HOEK_NK_CELL_2011_2012_TIV_7D_VS_0DY_ADULT_7D_DN
HOEK_NK_CELL_2011_2012_TIV_ADULT_1DY_UP
HOEK_NK_CELL_2011_2012_TIV_ADULT_3DY_UP
HOEK_NK_CELL_2011_2012_TIV_ADULT_7DY_UP
HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_1DY_DN
HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_1DY_UP
HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_3DY_DN
HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_3DY_UP
HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_7DY_DN
HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_7DY_UP
HOEK_T_CELL_2011_2012_TIV_ADULT_1DY_DN
HOEK_T_CELL_2011_2012_TIV_ADULT_1DY_UP
HOEK_T_CELL_2011_2012_TIV_ADULT_3DY_DN
HOEK_T_CELL_2011_2012_TIV_ADULT_3DY_UP
HOEK_T_CELL_2011_2012_TIV_ADULT_7DY_UP
HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_DN
HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_UP
HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_7DY_DN
HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_7DY_UP
HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_DN
HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_UP
HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_7DY_TOP_100_DEG_EX_VIVO_DN
HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_7DY_TOP_100_DEG_EX_VIVO_UP
HOFT_PBMC_TICE_BCG_RBCG_AG85A_AG85B_AGE_18_40YO_CORRELATED_WITH_WHOLE_BLOOD_BACTERICIDAL_ACTIVITY_NEGATIVE
HOWARD_B_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP
HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN
HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP
HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP
HOWARD_MONOCYTE_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN
HOWARD_MONOCYTE_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP
HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN
HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP
HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_DN
HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP
HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP
HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_28DY_DN
HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP
HOWARD_PBMC_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_19_39YO_AS03_ADJUVANT_VS_BUFFER_1DY_DN
HOWARD_PBMC_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_19_39YO_AS03_ADJUVANT_VS_BUFFER_1DY_UP
HOWARD_T_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP
KANNAN_BLOOD_2012_2013_TIV_AGE_65PLS_REVACCINATED_IN_6_9_MO_VS_REVACCINATED_IN_12_13_MO_UP
KANNAN_BLOOD_2012_2013_TIV_AGE_65PLS_REVACCINATED_IN_6_9_MO_VS_REVACCINATED_IN_12_13_MOS_DN
KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_AGE_UNKNOWN_CORRELATED_WITH_PROTECTION_56DY_NEGATIVE
KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_AGE_UNKNOWN_CORRELATED_WITH_PROTECTION_56DY_POSITIVE
KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_UNKN_AGE_IMM_WITH_ARR_VS_IMM_BY_RRR_PRIMARY_IMMUNIZ_WITH_RECOMB_ADENOVIRUS_35_1DY_UP
KENNEDY_PBMC_DRYVAX_AGE_18_40YO_STIMULATED_VS_UNSTIMULATED_1_TO_48MO_TOP_DEG_DN
KENNEDY_PBMC_DRYVAX_AGE_18_50YO_STIMULATED_VS_UNSTIMULATED_1_TO_48MO_TOP_DEG_UP
LI_PBMC_MENACTRA_AGE_18_45YO_7DY_UP
LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_DN
LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_UP
LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_DN
LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_UP
LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_NEGATIVE
LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_POSITIVE
LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_POLYSACCHARIDE_ANTIBODY_3DY_NEGATIVE
LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_POLYSACCHARIDE_ANTIBODY_3DY_POSITIVE
LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_DN
LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_UP
LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_CORRELATED_WITH_ANTIBODY_RESPONSE_3DY_NEGATIVE
LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_CORRELATED_WITH_ANTIBODY_RESPONSE_3DY_POSITIVE
LI_PBMC_ZOSTAVAX_AGE_25_40_AND_60_79YO_1DY_UP
LI_PBMC_ZOSTAVAX_AGE_25_40_AND_60_79YO_3DY_UP
MATSUMIYA_BLOOD_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_1DY_DN
MATSUMIYA_BLOOD_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_1DY_UP
MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_2DY_UP
MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_HIGH_RESPONDERS_VS_LOW_RESPONDERS_0DY_UP
MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_LOW_VS_HIGH_RESPONDERS_2DY_GO_T_CELL_ACTIV_AND_CO_STIM_UP
MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP
MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_WILD_TYPE_MVA_6HR_UP
MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_BCG_PRIMED_28DY_UP
MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_28DY_UP
NAKAYA_B_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN
NAKAYA_B_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP
NAKAYA_B_CELL_FLUMIST_AGE_18_50YO_7DY_DN
NAKAYA_B_CELL_FLUMIST_AGE_18_50YO_7DY_UP
NAKAYA_MONOCYTE_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN
NAKAYA_MONOCYTE_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP
NAKAYA_MONOCYTE_FLUMIST_AGE_18_50YO_7DY_DN
NAKAYA_MONOCYTE_FLUMIST_AGE_18_50YO_7DY_UP
NAKAYA_MYELOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN
NAKAYA_MYELOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP
NAKAYA_MYELOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN
NAKAYA_MYELOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP
NAKAYA_PBMC_FLUAD_IMUVAC_MALE_AGE_14_27YO_CORRELATED_WITH_HAI_RESPONSE_MF59_ADJUVANTED_AND_NON_1DY_GENES_IN_BTM_M75_POSITIVE
NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_ATIV_UP
NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_GENES_IN_BTM_M40_AND_M53_DN
NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_GENES_IN_BTM_M40_AND_M53_UP
NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_DN
NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_UP
NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN
NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP
NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_NEGATIVE
NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_POSITIVE
NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_NEGATIVE
NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_POSITIVE
NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN
NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_IFN_SUBSET_UP
NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_UP
NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_DN
NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_IFN_SUBSET_DN
NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_IFN_SUBSET_UP
NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_UP
NAKAYA_PBMC_IMUVAC_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0DY_PREIMM_TIV_UP
NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN
NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP
NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN
NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP
OCONNOR_PBMC_MENVEO_ACWYVAX_AGE_30_70YO_7DY_AFTER_SECOND_DOSE_VS_7DY_AFTER_FIRST_DOSE_DN
OCONNOR_PBMC_MENVEO_ACWYVAX_AGE_30_70YO_7DY_AFTER_SECOND_DOSE_VS_7DY_AFTER_FIRST_DOSE_UP
OSMAN_BLOOD_CHAD63_KH_AGE_18_50YO_HIGH_DOSE_SUBJECTS_24HR_DN
OSMAN_BLOOD_CHAD63_KH_AGE_18_50YO_HIGH_DOSE_SUBJECTS_24HR_UP
OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_0DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_DN
OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_0DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_UP
OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_3DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_DN
OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_3DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_UP
OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_0DY_DN
OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_0DY_UP
OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_28DY_DN
OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_28DY_UP
PANAPASA_BLOOD_FLUENZ_AGE_03_17YO_3DY_4DY_DN
PANAPASA_BLOOD_FLUENZ_AGE_03_17YO_6DY_7DY_UP
PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_3DY_DN
PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_3DY_UP
PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_DN
PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_TOP_30_DEG_UP
PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_UP
PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGED_POST_VACCINATION_VS_UNCHALLENGED_72HR_TOP_30_DEG_UP
QI_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_DN
QI_NAIVE_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_DN
QI_NAIVE_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_UP
QI_PBMC_ZOSTAVAX_AGE_50_75YO_1DY_UP
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_28D_PEAK_T_CELL_RESPONSE_14DY_NEGATIVE
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DY_AT_1DYPOSITIVE
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_EXPANSION_OF_VZV_SPECIFIC_T_CELLS_TO_PEAK_AT_1DY_NEGATIVE
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_EXPANSION_OF_VZV_SPECIFIC_T_CELLS_TO_PEAK_AT_1DY_POSITIVE
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_T_CELL_RESPONSES_1D_INFORMATIVE_OF_LONG_TERM_RESPONSES_NEGATIVE
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_T_CELL_RESPONSES_EXPANSION_AND_CONTRACTION_1D_NOT_INFORMATIVE_OF_LONG_TERM_RESPONSES_POSITIVE
QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_0_TO_35DY_JOINTLY_UP
QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_0DY_UP
QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_28DY_DN
QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_28DY_UP
QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_35DY_UP
QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_3DY_UP
QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_7DY_UP
QUEREC_MODEL_PBMC_YF_17D_VACCINE_AGE_18_45_7DY_PREDICTIVE
QUEREC_MODEL_PBMC_YF_17D_VACCINE_AGE_18_45YO_3DY_PREDICTIVE
QUEREC_PBMC_YF_17D_VACCINE_AGE_18_45YO_3DY_UP
QUEREC_PBMC_YF_17D_VACCINE_AGE_18_45YO_7DY_UP
RECHTIEN_PBMC_RVSV_ZEBOV_AGE_18_55YO_1DY_UP
RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_0W_14W_METALLOTHIONEIN_SUBSET_UP
RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_INTERFERON_SUBSET_UP
RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_SIGNIFICANT_VARIATION_UP
RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_TOP_FUNCTIONAL_NETWORK_UP
SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_2_TO_4DY_DN
SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_2_TO_4DY_UP
SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_50_TO_60DY_DN
SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_50_TO_60DY_UP
SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_5_TO_7DY_DN
SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_5_TO_7DY_UP
SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_5_TO_7DY_DN
SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_5_TO_7DY_UP
SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP
SCHERER_PBMC_YF_VAX_AGE_18_40YO_4_TO_7DY_DN
SCHERER_PBMC_YF_VAX_AGE_18_40YO_4_TO_7DY_UP
SCHERER_PBMC_YF_VAX_AGE_18_40YO_ANYD_DN
SCHERER_PBMC_YF_VAX_AGE_18_40YO_ANYD_UP
SCHERER_PBMC_YF_VAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP
SCHERER_PBMC_YF_VAX_OR_APSV_WETVAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_DN
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_1DY_UP
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_7DY_DN
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_CORRELATED_WITH_AGE_1DY_POSITIVE
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_CORRELATED_WITH_TRANSITIONAL_B_CELLS_UP
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_TRANSIENT_UP
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_LOW_VS_MEDIUM_HIGH_ADVERSE_EVENT_SUBJECTS_0DY_DN
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_MEDIUM_HIGH_ADVERSE_EVENT_SUBJECTS_1DY_UP
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_DN
SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_RESPONDERS_VS_NONRESPONDERS_7DY_UP
SOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_1DY_UP
SOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_7DY_DN
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_28DY_DN
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_28DY_UP
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_7DY_DN
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_7DY_UP
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_DN
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_UP
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_DN
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_UP
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_VS_70PLS_0DY_UP
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_NONRESPONDER_2DY_DN
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_NONRESPONDER_2DY_UP
THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_VS_21_30YO_0DY_UP
TSANG_PBMC_FLUVIRIN_PANDEMRIX_ADULT_CORR_WITH_CELL_FREQ_CD27HI_CD38HI_CD20_NEG_PLASMABLASTS_AND_CD38PLUS_OF_IGD_CD27PLUS_MEM_B_CELLS_7DY_POSITIVE
VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_8MO_UP
VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_DN
VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_UP
VOIGT_PBMC_FLUARIX_AGE_50_74YO_FEMALES_VS_MALES_0DY_TO_28D_UP
WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_ANTI_HBS_CONC_PRIMARY_VACC_1DY_SIGNIFICANT
WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_30_PRIMARY_VACC_1DY_POSITIVE
WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_4_POST_BOOSTER_VACC_1DY_POSITIVE
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_ADDNL_EXON_LVL_UP
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_DN
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_UP
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_3DY_DN
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_3DY_UP
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_AD5_NAB_TITERS_GT_200_VS_LTE_200_1DY_DN
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_AD5_NAB_TITERS_GTE_200_VS_LTE_200_1DY_UP
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_CORRELATED_WITH_CD8_T_CELL_RESPONSE_3DY_NEGATIVE
ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_CORRELATED_WITH_CD8_T_CELL_RESPONSE_3DY_POSITIVE